AJP - Endo Journal of Applied Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (March 29, 2005). doi:10.1152/ajpendo.00055.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/E328    most recent
00055.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Golfman, L. S.
Right arrow Articles by Taegtmeyer, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Golfman, L. S.
Right arrow Articles by Taegtmeyer, H.
Submitted on February 8, 2005
Accepted on March 24, 2005

Activation of PPAR{gamma} enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats

Leonard S. Golfman1, Christopher R. Wilson1, Saumya Sharma1, Mathias Burgmaier1, Martin E. Young2, Patrick H. Guthrie1, Melissa Van Arsdall1, Julia V. Adrogue1, Kathleen K. Brown3, and Heinrich Taegtmeyer1*

1 Division of Cardiology, University of Texas Medical School at Houston, Houston, Texas, USA
2 Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, USA
3 GlaxoSmithKline, Research Triangle Park, North Carolina, USA

* To whom correspondence should be addressed. E-mail: Heinrich.Taegtmeyer{at}uth.tmc.edu.

Background: It is suggested that insulin resistance and metabolic maladaptation of the heart are causes of contractile dysfunction. We tested the hypothesis whether systemic PPAR{gamma} activation, by changing the metabolic profile in a model of insulin resistance and type 2 diabetes (the ZDF rat) in vivo, improves contractile function of the heart in vitro. Methods and Results: Male Zucker diabetic fatty (ZDF) and Zucker Lean (ZL) rats, at 53-56 days of age, were treated with either GI262570 (a non-TZD PPAR{gamma} agonist; A) or vehicle (V) for one week. Agonist treatment resulted in correction of hyperglycemia and dyslipidemia, as well as in reduced hyperinsulinemia. The accumulation of triacylglycerols in the myocardium, characteristic of the ZDF rat, disappeared with treatment. Cardiac power and rates of glucose oxidation in the isolated working heart were significantly reduced in ZDF-V rats, but both parameters increased to non-diabetic levels with agonist treatment. In ZDF-V hearts, transcript levels of PPAR{alpha}-regulated genes and of MHC{beta} were upregulated, while GLUT-4 was downregulated compared to ZL. Agonist treatment of ZDF rats reduced PPAR{alpha}-regulated genes, and increased transcripts of GLUT-4 and GLUT-1. Conclusion: By changing the metabolic profile, reducing myocardial lipid accumulation and promoting the downregulation of PPAR{alpha}-regulated genes, PPAR{gamma} activation leads to an increased capacity of the myocardium to oxidize glucose and to a tighter coupling of oxidative metabolism and contraction in the setting of insulin resistance and type-2 diabetes.




This article has been cited by other articles:


Home page
DMMHome page
H. Bugger and E. D. Abel
Rodent models of diabetic cardiomyopathy
Dis. Model. Mech., September 1, 2009; 2(9-10): 454 - 466.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc ImagingHome page
K. I. Shoghi, B. N. Finck, K. B. Schechtman, T. Sharp, P. Herrero, R. J. Gropler, and M. J. Welch
In Vivo Metabolic Phenotyping of Myocardial Substrate Metabolism in Rodents: Differential Efficacy of Metformin and Rosiglitazone Monotherapy
Circ Cardiovasc Imaging, September 1, 2009; 2(5): 373 - 381.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
Y.-G. Niu and R. D. Evans
Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes
J. Physiol., July 1, 2009; 587(13): 3301 - 3315.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. W. van der Meer, L. J. Rijzewijk, H. W.A.M. de Jong, H. J. Lamb, M. Lubberink, J. A. Romijn, J. J. Bax, A. de Roos, O. Kamp, W. J. Paulus, et al.
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
Circulation, April 21, 2009; 119(15): 2069 - 2077.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
R. Palanivel, V. Vu, M. Park, X. Fang, and G. Sweeney
Differential impact of adipokines derived from primary adipocytes of wild-type versus streptozotocin-induced diabetic rats on glucose and fatty acid metabolism in cardiomyocytes
J. Endocrinol., December 1, 2008; 199(3): 389 - 397.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Taegtmeyer and R. Harmancey
Virchow's Metamorphosis Revealed: Triglycerides in the Heart
J. Am. Coll. Cardiol., September 16, 2008; 52(12): 1013 - 1014.
[Full Text] [PDF]


Home page
Physiol. Rev.Home page
E. D. Abel, S. E. Litwin, and G. Sweeney
Cardiac Remodeling in Obesity
Physiol Rev, April 1, 2008; 88(2): 389 - 419.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
R. D. Evans and Y. Niu
Hypolipidaemic effects of high-dose insulin therapy
Br. J. Anaesth., April 1, 2008; 100(4): 429 - 433.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. P. Chandler, E. E. Morgan, T. A. McElfresh, T. A. Kung, J. H. Rennison, B. D. Hoit, and M. E. Young
Heart failure progression is accelerated following myocardial infarction in type 2 diabetic rats
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1609 - H1616.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Boudina and E. D. Abel
Diabetic Cardiomyopathy Revisited
Circulation, June 26, 2007; 115(25): 3213 - 3223.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. D. Hafstad, A. M. Khalid, O.-J. How, T. S. Larsen, and E. Aasum
Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1288 - E1294.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
N. Fulop, M. M. Mason, K. Dutta, P. Wang, A. J. Davidoff, R. B. Marchase, and J. C. Chatham
Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1370 - C1378.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
L. K. Gerber, B. J. Aronow, and M. A. Matlib
Activation of a novel long-chain free fatty acid generation and export system in mitochondria of diabetic rat hearts
Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1198 - C1207.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. An and B. Rodrigues
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. J. Welch, J. S. Lewis, J. Kim, T. L. Sharp, C. S. Dence, R. J. Gropler, and P. Herrero
Assessment of Myocardial Metabolism in Diabetic Rats Using Small-Animal PET: A Feasibility Study
J. Nucl. Med., April 1, 2006; 47(4): 689 - 697.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. G. Poornima, P. Parikh, and R. P. Shannon
Diabetic Cardiomyopathy: The Search for a Unifying Hypothesis
Circ. Res., March 17, 2006; 98(5): 596 - 605.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.